open access

Vol 14, No 6 (2019)
Heart failure
Get Citation

Cardiac amyloidosis — state-of-the-art diagnosis and emerging therapies

Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś
Folia Cardiologica 2019;14(6):625-633.

open access

Vol 14, No 6 (2019)
Heart failure

Abstract

Cardiac amyloidosis (CA), which used to be considered a rare disease, is now increasingly recognised due to increased clinical awareness and the availability of advanced diagnostic techniques. CA can occur unexpectedly frequently in particular patient populations: among patients with heart failure with preserved left ventricular ejection fraction, as a phenocopy of hypertrophic cardiomyopathy, and among older patients with severe aortic stenosis. The deposition of abnormally folded, insoluble proteins in the extracellular matrix of tissues and organs plays a key role in the pathogenesis of amyloidosis. Despite the large number of pathogenic molecules, two types account for more than 95% of CA cases: immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). A recent paradigm shift in the diagnosis of CA, without the need for performing endomyocardial biopsy, has occurred as a result of technological advances in imaging and the development of new scintigraphy protocols. A combination of positive scintigraphic examination performed with bone-avid tracers and the absence of detectable monoclonal protein in serum or urine justifies a non-invasive diagnosis of ATTR. Early identification of affected patients remains crucial in order to improve prognosis, especially in patients with AL, in whom progression of the disease from the moment of heart involvement is extremely swift without causal treatment. There has recently been an exponential development of novel agents designed for patients with cardiomyopathy in the course of ATTR, which as a result, hopefully, in the future could become a curable disease. In the following article we present recent advances in the diagnosis and treatment of CA.

Abstract

Cardiac amyloidosis (CA), which used to be considered a rare disease, is now increasingly recognised due to increased clinical awareness and the availability of advanced diagnostic techniques. CA can occur unexpectedly frequently in particular patient populations: among patients with heart failure with preserved left ventricular ejection fraction, as a phenocopy of hypertrophic cardiomyopathy, and among older patients with severe aortic stenosis. The deposition of abnormally folded, insoluble proteins in the extracellular matrix of tissues and organs plays a key role in the pathogenesis of amyloidosis. Despite the large number of pathogenic molecules, two types account for more than 95% of CA cases: immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). A recent paradigm shift in the diagnosis of CA, without the need for performing endomyocardial biopsy, has occurred as a result of technological advances in imaging and the development of new scintigraphy protocols. A combination of positive scintigraphic examination performed with bone-avid tracers and the absence of detectable monoclonal protein in serum or urine justifies a non-invasive diagnosis of ATTR. Early identification of affected patients remains crucial in order to improve prognosis, especially in patients with AL, in whom progression of the disease from the moment of heart involvement is extremely swift without causal treatment. There has recently been an exponential development of novel agents designed for patients with cardiomyopathy in the course of ATTR, which as a result, hopefully, in the future could become a curable disease. In the following article we present recent advances in the diagnosis and treatment of CA.
Get Citation

Keywords

amyloidosis, light-chain amyloidosis, transthyretin amyloidosis, transthyretin, cardiomyopathy, heart failure

About this article
Title

Cardiac amyloidosis — state-of-the-art diagnosis and emerging therapies

Journal

Folia Cardiologica

Issue

Vol 14, No 6 (2019)

Pages

625-633

Bibliographic record

Folia Cardiologica 2019;14(6):625-633.

Keywords

amyloidosis
light-chain amyloidosis
transthyretin amyloidosis
transthyretin
cardiomyopathy
heart failure

Authors

Katarzyna Holcman
Magdalena Kostkiewicz
Piotr Podolec
Paweł Rubiś

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl